David Lewis

Join Krish Patel, an expert in mantle cell lymphoma from the Sarah Cannon Cancer Institute, and David Lewis from Plymouth University, as they discuss the groundbreaking role of BTK inhibitors in treating relapsed/refractory MCL. They explore innovative combination strategies to tackle resistance and enhance treatment efficacy. The conversation highlights the importance of personalized therapy and the evolving landscape of BTK inhibitor selection, particularly in the UK. Their insights reveal promising future directions in MCL management.